CTX112

CTX112 is a CAR-T cell therapy developed by CRISPR Therapeutics. Its target is CD19 (the sponsor names CD19). The sponsor states: An allogeneic CD19-directed CAR T-cell immunotherapy made from donor T cells genetically modified ex vivo using CRISPR-Cas9 gene editing (single guide RNA and Cas9 nuclease) to attack CD19-expressing B-cell malignancies. ClinicalTrials.gov describes the intervention as: CTX112 (CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hodgkin lymphoma, chronic lymphocytic leukaemia, follicular lymphoma, mantle cell lymphoma and diffuse large B-cell lymphoma. The largest, NCT05643742, plans to enrol 120 participants with primary completion expected 2030-01. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.